Telix Pharmaceuticals Insider Trades
NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 3 · $1.02M
- Sales
- 0 · $0
- Shares bought / sold
- 70.01K / 0
- Net activity
- Net buying $1.0 million
Telix Pharmaceuticals insider activity
Over the last 12 months, Telix Pharmaceuticals insiders reported 4 transactions on SEC Form 4: 3 open-market purchases and 0 sales. Insiders bought $1.0 million and sold $0 worth of stock, for net insider buying of $1.0 million. The most recent filing shows Smith Darren Charlton (Group Chief Financial Officer) buying 2,071 shares at $9.66 on Sep 7, 2026.
Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put TLX's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
TLX insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 7, 2026 | Smith Darren CharltonGroup Chief Financial Officer | Buy | 2,071 | $20.00K | Form 4 |
| Apr 29, 2026 | Behrenbruch ChristianMD & Group CEO | Buy | 33,435 | $497.18K | Form 4 |
| Apr 28, 2026 | Behrenbruch ChristianMD & Group CEO | Buy | 34,500 | $499.56K | Form 4 |
| Mar 29, 2026 | Smith Darren CharltonGroup Chief Financial Officer | Option exercise | 1,111 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4